Why is Broadcom stock sliding today?

Broadcom shares fell nearly 4.9% to $328.12 amid a semiconductor selloff triggered by Intel’s weak fourth-quarter outlook; Intel forecast adjusted EPS of $0.25 and revenue of $15 billion-$16 billion. Broadcom also faced a William Blair downgrade, valuation concerns, and potential exposure of up to $43 billion tied to its Anthropic financing arrangement, while Fitch maintained its A- rating with a positive outlook. Broadcom had previously guided for fiscal Q4 2026 gross margin of about 73%, down from 78% a year earlier, despite expected revenue of $34.8 billion; the Nasdaq fell 2.1% and the S&P 500 declined 1.3%.

Analysis

AVGO’s decline appears to combine broad de-risking with a company-specific rerating risk; the Intel read-through is weaker than the market reaction implies. PC weakness is not direct evidence that demand for Broadcom’s custom AI silicon is weakening. The more relevant transmission is investor concern that AI infrastructure budgets may be less durable or less profitable than assumed, amplified by Amazon capex scrutiny and Broadcom’s customer concentration. Higher-memory custom-chip mix also means accelerating sales need not translate into comparable gross-profit growth: the margin trajectory, not revenue alone, is the key near-term test.

Over days, risk-off flows and elevated valuation sensitivity can extend the move without new AVGO-specific information. Over 1–3 months, the next earnings report and any evidence on customer concentration, AI program ramps, and margin stabilization are the catalysts. Over 6–18 months, custom silicon adoption could support demand, but customer bargaining power and mix-driven margin pressure may limit the earnings multiple. The Anthropic backstop is contingent exposure, not an established loss; verify deal terms, funding structure, and collateral before treating it as a credit event. The Form 4 is not directional without transaction type and size.

Contrarian angle: the selloff may be over-penalizing AVGO for Intel’s PC outlook, but a lower entry price alone does not resolve the more consequential concentration and margin questions. A relative-value position is preferable to an outright call while those remain unverified.

Key Decisions for Investors

• Avoid chasing the opening selloff. Keep AVGO exposure below benchmark pending stabilization and clearer evidence that AI-related gross-profit dollars are holding up despite mix pressure.
• For a 1–3 month relative-value expression, consider a small, risk-defined short AVGO versus a long broad semiconductor basket excluding AVGO, sized to limit sector beta. Reassess after subsequent guidance; this is a relative-value thesis, not a claim that the whole AI chip cycle has peaked.
• Falsify the underweight thesis if AVGO reports margin performance or guidance materially better than the indicated mix pressure suggests, while customer concentration and financing terms remain manageable. Conversely, worsening margin guidance, a delayed major AI program, or adverse financing terms would strengthen it.
• Treat the Anthropic exposure and Form 4 as diligence alerts, not stand-alone sell signals: verify whether the backstop is funded or contingent, recourse and collateral provisions, and the insider filing’s transaction type and amount before changing risk.